Shanghai Fosun Pharmaceutical (Group) Co., Ltd.SSE: 600196

Announcement on Approval of Supplementary Drug Application by Holding Subsidiary

· Issued by Shanghai Fosun Pharmaceutical (Group) Co., Ltd. via Shanghai Stock Exchange

Filed with SSE · · 2 pages · Chinese

Summary by 6ix AI

Shanghai Fosun Pharmaceutical (Group) Co., Ltd. announced that its subsidiary has received approval for a supplementary drug application. The approved drug, Hanlikang, is a biosimilar of rituximab and will now have expanded indications for treating adult patients with diffuse large B-cell lymphoma. This approval is expected to provide more treatment options for patients and may impact the company's market position. However, the company warns that sales may be influenced by various market factors, introducing uncertainty.

Written in English by 6ix AI from the company’s Chinese-language filing. How 6ix writes summaries

Release

Announcement on Approval of Supplementary Drug Application by Holding Subsidiary

The abstract is for reference only. Please refer to the full text of the announcement on the very day.

Link of Full Text for Reference:

Shanghai Fosun Pharmaceutical (Group) Co., Ltd. on 6ix

Earlier from Shanghai Fosun Pharmaceutical (Group)

Later from Shanghai Fosun Pharmaceutical (Group)

All Shanghai Fosun Pharmaceutical (Group) news releases